For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Teriparatide
Illustration for Teriparatide

THE PEPSRADAR ENCYCLOPEDIA

Teriparatide

Parathyroid-hormone-related bone formation

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Teriparatide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Teriparatide) on DailyMed ↗

What is Teriparatide?

Teriparatide is a parathyroid-hormone-related medicine used in osteoporosis care. Fracture reduction is a more direct clinical outcome than a bone marker alone.

Biological role or research focus

Parathyroid-hormone-related bone formation.

The relevant clinical setting is osteoporosis with high fracture risk, not broad performance enhancement.

Role reference: MedlinePlus · Teriparatide ↗

Names you may encounter

Forteo

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
PTH(1–34) analogue
Main research area
Bone formation and fracture prevention
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Teriparatide ↗

Quick answers

Is Teriparatide FDA approved?
Yes. Forteo (NDA 021318, approved 2002), Bonsity and other teriparatide injections for osteoporosis at high fracture risk. Source ↗
Is Teriparatide safe?
Teriparatide builds bone in osteoporosis; joint pain and nausea are common, and the label warns of bone cancer (osteosarcoma) seen in rats, high calcium and dizziness on standing. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Teriparatide banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Fracture Prevention Trial (2001)Human randomized trial1,637 postmenopausal women with prior vertebral fractures.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2001

Fracture Prevention Trial

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

Population / model
1,637 postmenopausal women with prior vertebral fractures.
Study design
Two PTH(1–34) groups versus placebo; median observation 21 months.
Main finding
New vertebral fractures occurred in 14% with placebo versus 5% and 4% in the active groups. Bone mineral density also increased.
Limits & context
This is fracture-prevention evidence in osteoporosis. It does not establish accelerated healing of every sports injury or benefit in people with normal bone density.

Source: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

84 registered studies name Teriparatide as an intervention among the 100 most recently updated of 182 search results; 11 are recruiting or under way, 3 have not started recruiting yet, 51 completed and 19 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Combined Anabolic Therapy
NCT06558188 · Massachusetts General Hospital
RecruitingPhase 42025-02-0350
PROactive HEALing in High-Risk Pelvic and Non-hip Lower Extremity Fragility Fractures (PRO HEAL Pilot)
NCT06303284 · University of Calgary
Not yet recruitingPhase 1 / Phase 22027-03-1554
Novel Combination Therapy for Osteoporosis in Men
NCT03994172 · VA Office of Research and Development
CompletedPhase 42019-07-0140
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
NCT07242612 · Khyber Medical University Peshawar
CompletedNot applicable2025-10-0140
Sequential Therapies After Osteoanabolic Treatment
NCT06164795 · 424 General Military Hospital
Recruiting2023-11-25150
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
NCT03735537 · University of Edinburgh
CompletedPhase 42016-11-01350
Teriparatide (Forsteo) Treatment in Postmenopausal Women: Mechanism of Action
NCT01293292 · Sheffield Teaching Hospitals NHS Foundation Trust
CompletedPhase 42011-0119
Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover
NCT05151484 · Madhumathi Rao
Active, not recruitingPhase 42022-03-2160

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 84 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. ↗
Lancet (London, England) · 2015 Sep 19 · Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Read available full text ↗

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials. ↗
Medicine · 2017 May · Comparative Study, Journal Article, Meta-Analysis, Systematic Review
Read available full text ↗

Teriparatide. ↗
· 2012 · Review

PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. ↗
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025 Jun · Journal Article, Network Meta-Analysis, Systematic Review
Read available full text ↗

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Teriparatide builds bone in osteoporosis; joint pain and nausea are common, and the label warns of bone cancer (osteosarcoma) seen in rats, high calcium and dizziness on standing.

Human safety data: FDA label

Safety is established by FDA labeling and long clinical use. Observational studies in people have not shown a higher osteosarcoma risk, but data beyond two years of use are limited. It is not approved for children.

Take extra care with: Heart or blood pressure problemsCancer, now or in the pastKidney problems

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • History of severe allergy to teriparatide or any ingredient
  • Higher osteosarcoma risk, such as Paget's disease, bone cancer or bone metastases, or past radiation to the skeleton: label says avoid
  • Children and young adults whose growth plates are still open: label says avoid
  • Underlying high-calcium disorders: label says avoid

Interactions

  • Digoxin: temporary rises in blood calcium may increase the risk of digoxin toxicity

Serious risks

  • Osteosarcoma (bone cancer) in rats, with rare reports in people
  • Severe allergic reactions, including anaphylaxis and angioedema
  • High blood calcium and worsening skin calcification
  • Worsening kidney stones
  • Dizziness or fainting on standing (orthostatic hypotension)

Common side effects

  • joint pain
  • pain
  • nausea

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Forteo (teriparatide) prescribing information ↗

Key precautions

Elevated calcium, kidney stones, dizziness, and specific bone-cancer risk factors require review. Prior skeletal radiation and other bone disorders can affect suitability.

Source: MedlinePlus · Teriparatide ↗

Regulatory status

U.S. FDA approval
Approved
Forteo (NDA 021318, approved 2002), Bonsity and other teriparatide injections for osteoporosis at high fracture risk. source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

The medication reference describes osteoporosis treatment in selected patients. The trial below concerns postmenopausal women with previous vertebral fractures, a population with substantial baseline risk.

Source: MedlinePlus · Teriparatide ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

Its therapeutic action promotes bone formation and increases bone strength and density. Those actions are studied in a defined bone-disease context.

Source: MedlinePlus · Teriparatide ↗

Molecular structure

Teriparatide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 16133850 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • The relevant clinical setting is osteoporosis with high fracture risk, not broad performance enhancement.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Does fracture prevention prove faster healing of an existing injury?

No. Preventing a new fracture and healing an existing one are different clinical questions.

Source: MedlinePlus · Teriparatide ↗

Can the trial results be applied to people with normal bone density?

Not directly. Baseline risk and the condition being treated strongly affect benefit and harm.

Source: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Teriparatide

Download illustration ↓Source record ↗
Teriparatide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.